Results 141 to 150 of about 1,923,290 (310)

RELA Ablation Contributes to Progression of Hepatocellular Carcinoma with TP53R249S Mutation and is a Potential Therapeutic Target

Advanced Science, EarlyView.
Genome‐wide CRISPR/Cas9 based screening identified RELA as a key tumor suppressor in TP53R249S‐mutant HCC. Its loss promotes tumorigenesis and metastasis via DVL1‐mediated Wnt/β‐catenin activation, while its agonist betulinic acid suppresses tumor progression.
Zhiping Wu, Zhe Wang, Diwei Zheng, Yongfang Zheng, Zhiwu Jiang, Jiang Lv, Yueqin Zhu, Heng Jia, Ziyuan Duan, Tingjie Yuan, Qiting Wu, Youguo Long, Shouheng Lin, Yao Yao, Georgia Carson, Jean P. Thiery, Kwan Man, Peng Li   +17 more
wiley   +1 more source

Organelle-Partitioned Sugar–Rhodamine Diad for In Vivo Tumor Imaging

ACS Omega, 2020
Enkang Zhang, Chaozhang Yu, Hui Tang, Yuntong Li, Dongliang Zuo, Rongshui Yang, Chao Ma, Jiayin Miao, Pingguo Liu, Xinhui Su   +9 more
doaj   +1 more source

HCC-Check: A Novel Diagnostic Tool for Early Detection of Hepatocellular Carcinoma Based on Cytokeratin-1 and Epithelial Membrane Antigen: A Cross-Sectional Study

Technology in Cancer Research & Treatment
Background: Hepatocellular carcinoma is frequently diagnosed in advanced stages, leading to a poorer prognosis. Therefore, early diagnosis and identification of biomarkers may significantly improve outcomes.
Kareem A. Attallah MSc, Mohamed S. Albannan PhD, Khaled Farid MD, PhD, Sherine M. Rizk PhD, Nevine Fathy PhD   +4 more
doaj   +1 more source

Liver transplantation [PDF]

, 2014
Purpose of review: Long-term survival of liver transplant recipients is threatened by increased rates of de-novo malignancy and recurrence of hepatocellular carcinoma (HCC), both events tightly related to immunosuppression.
Burroughs, AK, De la Mata, M, Rodríguez-Perálvarez, M   +2 more
core  

Metabolic Pathways Enhancement Confers Poor Prognosis in p53 Exon Mutant Hepatocellular Carcinoma. [PDF]

, 2020
RNA-Sequencing (RNA-Seq), the most commonly used sequencing application tool, is not only a method for measuring gene expression but also an excellent media to detect important structural variants such as single nucleotide variants (SNVs), insertion ...
Chen, Po-Ming, Chiang, Eugene, Li, Jian-Rong, Liu, Chun-Chi, Tang, Feng-Yao   +4 more
core  

Combination immunotherapy for hepatocellular carcinoma.

Journal of Hepatology, 2023
L. Rimassa, R. Finn, B. Sangro
semanticscholar   +1 more source

Minimally Invasive Chemical Biopsy Needle with Self‐Wettable Extraction Phase For In Vivo Tissue Sampling During Medical Procedures

Advanced Science, EarlyView.
A new tissue sampling device using an acupuncture needle with bio‐compatible extraction sorbents in the recessed section is developed. The coating material using self‐wettable particles doesn't require solvent activation after sterilization. This device is applied for the anti‐cancer drug concentration monitoring during the in vivo lung perfusion ...
Runshan Will Jiang, Wei Zhou, Marcelo Cypel, Todd L. Demmy, Gal Shafirstein, Guillermo Garza, Emily Gawrys, Joanna Bogusiewicz, Barbara Bojko, Janusz Pawliszyn   +9 more
wiley   +1 more source

Discovery of a Potent and Selective TEAD Degrader with Durable Degradation Activity

Advanced Science, EarlyView.
KG‐FP‐003, a highly potent TEAD‐YAP PROTAC derived from the patented inhibitor is developed. It selectively degrades endogenous TEAD proteins in HiBiT systems without IMiD‐related off‐target effects. Screening across 867 cancer cell lines revealed broad and superior anti‐tumor activity, highlighting its therapeutic potential through targeted TEAD ...
Linhui Cao, Jing Yang, Yuhang Liu, Xiaotong Chen, Yufang Shi, Yunshuo Zhao, Yong Zhang, Jian Chen, Bowen Li, Wuqiang Wen, Lu Chen, Bo Peng, Lu Huang, Yanli Sun, Lixin Zhou, Matthew G Rees, Melissa M Ronan, Jennifer A Roth, Zhixiang Guo, Jing Xing, Guangya Zhu, Yazhou Wang, Baishan Jiang, Jing Lu, Kehao Zhao, Wenchao Lu   +25 more
wiley   +1 more source

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

The Lancet, 2018
R. Finn, S. Qin, K. Han, F. Piscaglia, A. Baron, Joong-Won Park, G. Han, J. Jassem, J. Blanc, A. Vogel, D. Komov, T. J. Evans, C. Lopez, C. Dutcus, M. Guo, Kenichi Saito, S. Kraljevic, T. Tamai, M. Ren, A. Cheng   +19 more
semanticscholar   +1 more source

A Patient‐Derived Organoid Biobank of Adamantinomatous Craniopharyngioma as a Platform for Drug Discovery

Advanced Science, EarlyView.
This study successfully establishes adamantinomatous craniopharyngioma (ACP) patient‐derived organoids (PDOs) that preserve the histopathological and genetic features of the original tumors. Through drug sensitivity assays and subsequent mechanistic analyses, the study demonstrates that Ceritinib exerts its inhibitory effects on ACP PDO growth by ...
Huarong Zhang, Chaohu Wang, Jun Fan, Zexin Chen, Haoying Yu, Yawen Bai, Tingcheng Zhang, Qianchao Zhu, Yiwen Feng, Peirong Niu, Jiaqian Chen, Liping Yang, Xueying Li, Lei Yu, Songtao Qi, Yi Liu   +15 more
wiley   +1 more source